About 95% of APL is typically characterized by the fusion between promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARA) and sensitive to differentiation induction therapy containing all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with a good clinical outcome. Here, RARA is linked to acute promyelocytic leukemia.